Audentes Therapeutics (BOLD) Tops Q2 EPS by 32c

Audentes Therapeutics (NASDAQ: BOLD) reported Q2 EPS of ($0.70), $0.32 better than the analyst estimate of ($1.02).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Raymond James on Whirlpool Corporation (WHR): 'July Major Appliance Industrial Production Remained Weak'
• Carvana (CVNA) call put ratio 1 call to 2.2 puts with a focus on August 60 puts as share price up 6.3%
• Trump: building a White House heliport donated by Sikorsky